The Effect of Lisinopril and Verapamil on Circulating Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201907856711564

Enrollment

120

Registered

2019-07-04

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

lisinopril

verapamil plus lisinopril

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T2DM patients aged between 45 and 65 years. 5 years’ disease duration. Active DN in the form of microalbuminuria (UACR: 30-300 mg/g) in two of three samples over a 3 months’ period prior to study. Hemoglobin A1C (HbA1c) =8.5%.

Exclusion criteria

Exclusion criteria: Active urinary tract infection. End Stage Renal disease. End Stage Liver disease. Cancer. Hematological disorders. Patients taking immunosuppressive medicine. a recent history of acute myocardial infarction, stroke, or occlusive.

Design outcomes

Primary

Measure	Time frame
urinary albumin creatinine ratio,endostatin and angiopoitien 2 kidney damage biomarkers	—

Secondary

Measure	Time frame
fasting blood glucose, glycated hemoglobin and lipid profile	—

Countries

Egypt

Contacts

Public ContactHala Elmosalamy

faculty of pharmacy ain shams univeristy

hala_elmosalamy@hotmail.com00201061669913

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026